ArticleOphthalmology science2026
Novel Systemic Associations of Idiopathic Epiretinal Membrane Identified via Machine Learning.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To discover novel systemic associations that may lead to idiopathic epiretinal membrane (iERM) using interpretable machine learning models. Design: Large data retrospective case-control study. Subjects: All of Us Dataset, including a total of 10 380 patients: 2015 iERM patients with 2015 1:1 matched controls, 3175 secondary epiretinal membrane (sERM) patients with 3175 1:1 matched controls. Methods: Electronic health records of epiretinal membrane (ERM) patients from the All of Us Research Program, a nationwide longitudinal cohort of US adults (data from 6/2016 to 2/2025) were collected. Unsupervised clustering using principal component analysis was performed on the data set to identify distinct patient subgroups. Supervised machine learning models, including gradient-boosted decision trees and logistic regression, were trained to predict iERM. Main Outcome Measures: Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), while feature importance was assessed using the Gini index for tree-based models and coefficient magnitudes for logistic regression. Additionally, odds ratios for comorbidities associated with both iERM and sERM were estimated using 2 × 2 contingency tables. Results: Unsupervised clustering of iERM patients revealed 4 distinct subgroups characterized by unique systemic comorbidity profiles, including cardiometabolic, dermatologic, and joint disorder pathways. Clusters demonstrated significant associations with systemic conditions such as hypertension, hyperlipidemia, type 2 diabetes, inflammatory skin conditions, osteoarthritis, and anemia. Supervised models, including logistic regression and gradient-boosted decision trees, achieved AUC values exceeding 0.679 on a testing set. Key predictors of iERM included knee osteoarthritis, hyperlipidemia, essential hypertension, and sensorineural hearing loss, each demonstrating high coefficient magnitudes, Gini importance, and statistically significant odds ratios. Conclusions: This study challenges conventional distinctions between iERM and sERM, proposing systemic comorbidities as associations to ERM development. The observed associations with cardiometabolic dysfunction, chronic inflammation, and joint and dermatologic disorders suggest that systemic mechanisms may significantly influence ERM pathogenesis. Future studies are necessary to establish causality and explore targeted therapeutic approaches, potentially incorporating anti-inflammatory treatments or cardiovascular risk management to prevent ERM formation. These findings highlight opportunities for personalized risk assessment and preventative interventions based on systemic comorbidity profiles. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.